AKT1 and breast carcinoma: Numerous studies have been conducted to investigate the therapeutic approaches for early-stage breast cancer, and inhibition of the PI3K/AKT/mTOR pathway has shown promising results (Cocco,et al., 2022; Zhu et al., 2023).